The primary strategy in HCC immunotherapy involves targeting immune checkpoints, most notably the programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) pathway. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.